Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates BRAF gene mutation subtypes correlate with patient age in metastatic melanoma, highlighting genotype testing to optimize drug therapy.
A mutation in the BRAF gene is key in skin melanoma. Its prevalence varies depending on the region of residence and other clinical and morphological characteristics. The determination of a mutation in the BRAF gene in patients with metastatic melanoma is a primary molecular genetic study that may influence the choice of drug therapy. As clinical studies have shown, it is important not only to determine the presence or absence of a mutation in the BRAF gene, but also to determine the genotype of the BRAF mutation, which has clinical and practical significance. In this article, we reviewed the results of our own research, assessed the prevalence of mutations in the BRAF gene and genotypes, and also correlated with the age of patients and the localization of melanoma.
No takes yet. Share an insight, caveat, or question.
Orlova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: